

## RAD51D Mutations

### Cancer Risks and General Management Recommendations

<b>RAD51D Mutation Carrier Cancer Risks</b>	<b>General Population Lifetime Cancer Risks</b>	<b>Surveillance/Management Recommendations<sup>1</sup></b>
<u>Ovarian Cancer</u> <sup>2,3</sup> 7-14%	1-2%	<p><i>Surgery</i></p> <ul style="list-style-type: none"> <li>Consider risk-reducing salpingo-oophorectomy (RRSO) at age 45-50 years, or earlier based on ovarian cancer family history                             <ul style="list-style-type: none"> <li>Insufficient evidence exists to recommend an optimal age for RRSO</li> </ul> </li> <li>Further pathological examination of the ovarian specimen on RRSO can yield greater detection of ovarian cancer, and should be considered in individuals with <i>RAD51D</i> mutations<sup>4</sup></li> </ul> <p><i>Surveillance</i></p> <ul style="list-style-type: none"> <li>For women who have not elected RRSO, transvaginal ultrasound combined with serum CA-125 for ovarian cancer may be considered at their clinician's discretion</li> <li>The benefit of ovarian cancer surveillance is uncertain at this time</li> </ul>

Breast cancer: The lifetime risk to develop breast cancer in women with a *RAD51D* mutation is currently unknown. Some studies indicate the *RAD51D* gene may not be associated with breast cancer at all,<sup>5</sup> but other studies show that it could be a low penetrant gene for breast cancer.<sup>6</sup> Current NCCN guidelines (v1.2020) state that there is a potential increased risk for triple-negative breast cancer, however there is insufficient evidence to recommend modified breast cancer risk management based on *RAD51D* mutation status alone. An individual's personal and family history should be considered in developing an appropriate surveillance plan.

Treatment: *RAD51D* mutation carriers may be sensitive to specific chemotherapy agents and thus may benefit from therapies suggested for *BRCA1* and *BRCA2* carriers, such as poly ADP ribose polymerase (PARP) inhibitors.

Other Cancer Risks: Preliminary evidence of an association between *RAD51D* mutations in prostate cancer has been proposed.<sup>7</sup> However, this association has not been completely established and more information is needed.

### Implications for Family Members/Reproductive Considerations

- First-degree relatives (i.e., parents, siblings, and children) have a 50% chance to have the familial *RAD51D* mutation. Second-degree relatives (i.e., nieces/nephews, aunts/uncles, and grandparents) have a 25% chance to have the familial mutation.
- For carriers of a known mutation, assisted reproduction (with or without egg or sperm donation), pre-implantation genetic testing, and prenatal diagnosis options exist.
- All family members are encouraged to pursue genetic counseling to clarify their risks. Family members can visit [www.FindAGeneticCounselor.com](http://www.FindAGeneticCounselor.com) to find genetic services near them.

## References

- NCCN v1.2020 Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic.
- Song H, et al. Contribution of Germline Mutations in the *RAD51B*, *RAD51C*, and *RAD51D* Genes to Ovarian Cancer in the Population. *J Clin Oncol*. 2015 10:2901-7. PMID: 26261251.

3. Tung, Nadine et al. "Counselling Framework for Moderate-Penetrance Cancer-Susceptibility Mutations." *Nature reviews. Clinical oncology* 13.9 (2016): 581–588. *PMC*. Web. 22 Feb. 2018.
4. Powell CB, et al. 2005. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. *Journal of Clinical Oncology*. 23(1):127-132.
5. Osher DJ et al. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. *Br J Cancer*. 2012; 106(8):1460-3.
6. Rodriguez-Lopez R et al. The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations. *Int J Cancer*. 2004; 110:845–849.
7. Pritchard, C.C. et al. "Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer." *The New England journal of medicine* 375.5 (2016): 443–453. *PMC*. Web. 22 Feb. 2018.